HDAC9 and breast carcinoma: Nevertheless, some PROTACs demonstrated selectivity in degrading specific HDAC isoforms, like HDAC3, exemplified by the synthesis reported by Xiao et al. of an HDAC3-selective degrader exhibiting significant potency in breast cancer cells [172,173,174,175].